







Partner

U.S.-India Business Council















Future Pavilion Partner

Pavilion Sta

Start-Up Partner Strategic Partner

Make in India Partner

Procurement Session Partners



Conference Program

Venue: Hall No 11 and 14, Bharat Mandapam

Day 1: September 4, 2025	
0900 onwards	Registration
By 1100	Audience to be seated in Inauguration Hall
1130 - 1240	Inaugural Session (Auditorium 2, Bharat Mandapam)
	 Welcome Address by Shri Nitin Kumar Yadav, IAS, Additional Secretary, Ministry of Commerce and Industry, Gol Special Address by Shri Amit Agrawal, IAS, Secretary, Department of Pharmaceuticals, Gol Award of ICMR Technologies to Industry Partner Launch of Movie of PHARMEXCIL on Indian Pharmaceutical Export Inaugural Address by Chief Guest: Shri J P Nadda, Hon'ble Minister for Chemicals & Fertilizers and Health & Family Welfare, Gol
	Vote of Thanks by Shri Namit Joshi, Chairman, Pharmexcil
1240 - 1300	Inauguration of MedTech Exhibition
1300 - 1430	CEO's Roundtable Meeting with Hon'ble Minister (By invite only)
	This exclusive, closed-door CEO Roundtable brings together the Hon'ble Minister and top leadership from Indian and global MedTech companies for a strategic dialogue on propelling India toward global leadership in medical technologies. The session serves as a platform for the industry's top decision-makers to engage directly with the government on shaping an enabling policy environment that attracts investment, advances innovation, and strengthens India's footprint in global value chains.
	Objective: To deliberate on a forward-looking roadmap that positions India as a leading global destination for MedTech innovation, manufacturing, and exports by addressing policy, regulatory, and trade-related enablers.
	 Key Discussion Points: Export Promotion Strategy: Identifying measures to enhance India's MedTech exports, integrate into global supply chains, and improve access to international markets Tariff & Non-Tariff Barriers: Addressing trade barriers that impact the competitiveness of Indian manufacturers and the entry of strategic technologies



	 Investment Facilitation: Exploring policy reforms and incentive structures to attract and retain long-term, high-value investments Innovation Enablement: Strengthening public-private collaboration to support R&D, product development, and commercialization pathways Ease of Doing Business: Streamlining approvals, single-window clearances, and state-level facilitation to improve operational efficiency Global Positioning: Identifying India's comparative advantages and defining a shared vision to position India as a MedTech innovation and export powerhouse
1315 -1445	Lunch
1400 - 1800	Buyer Seller Meet (Prefixed B2B, G2B meetings)
1530 - 1700	ICMR Pitching Session
	The session aims to showcase market-ready biomedical innovations (TRL-9) by promising startups, providing them a platform to pitch to investors, venture capitalists, and industry leaders. The event fosters investment, strategic partnerships, technology transfer, and scale-up opportunities. Networking sessions at the ICMR Pavilion will further enable collaborations and mentorship. Objective- Showcase indigenous medical research and innovation Promote regulatory and ethical standards in medical device R&D Enable industry partnerships for commercialization and global outreach Welcome Remarks- Dr Suchita Markan, Scientist F, Head, Innovation & Translation Unit, Mission in-charge MDMS, ICMR Setting the Context- Shri Rajib Sen, Senior Advisor, NITI Aayog Special Address- Dr Rajeev Singh Raghuvanshi, Drugs Controller General of India* Inaugural Address- Dr Rajiv Bahl, Secretary DHR & Director General, ICMR Technologies to be presented: Multi-parametric Diagnostics device Spandan ECG Prathamasense Geosensor device Kidney UACR Kit (PoC for Chronic Kidney Disease detection) EZ Check HB test InoHeal (Wound Healing Device) FibriTimer-Zeta 01: Multipurpose Hemostasis System for Small Throughput Labs Modular oxygen apparatus with variable flow and pressure control for oxygen supply Vote of Thanks- Dr Taruna Madan Gupta, Scientist-G, Head, Development Research Division
15:00- 16:30	Session 1: Global MedTech Manufacturing Hub: Precision Engineering yet Affordable
	India's MedTech industry stands at a transformative juncture, poised to emerge as a global leader in manufacturing and innovation hub. Driven by the need for world-class precision engineering and cost-effective access to medical technologies, the sector faces the challenge of balancing quality with affordability. As global demand for high-quality and cost-effective medical devices grows, India is leveraging the concept of Quality by Design by using world-class precision



	 engineering in MedTech Sector to position itself as a preferred manufacturing destination by complying requirement of Quality, Safety and Efficacy. This session will explore how India is evolving into global MedTech manufacturing hubs by using cutting-edge Precision Engineering in MedTech Sector. The discussion will bring together policymakers, Industry leaders, and innovators to share perspectives on adopting new technologies to produce high quality product with new innovation, scaling manufacturing capabilities, and ensuring affordability without compromising quality. Key Takeaways Precision engineering can be cost-effective when paired with strategic approaches, enabling the production of high-quality medical devices with zero defects. Quality by Design principles are critical for balancing innovation, affordability, and compliance in India's MedTech sector.
	Session Chair: Shri Amit Agrawal, IAS, Secretary, Department of Pharmaceuticals, Ministry of Chemicals & Fertilizers, Government of India Session Co-Chair: Dr Rajneesh, Additional Secretary and Development Commissioner (MSME), Ministry of MSME, Government of India Government Panelist: Dr Akshay Shrivastava, HOD-Medical Devices, NIPER Ahmedabad Prof Neetu Singh, Professor and Head, Center for Biomedical Engineering, IIT Delhi Session Moderator: Dr Smruthi Suryaprakash, Partner, BCG Industry Speakers: Ms Shuba Nagesh, Managing Director, GE BEL & GM ISC India, Wipro GE HealthCare Mr Rajiv Nath, Managing Director, HMD Mr Bharath Sesha, Managing Director & CEO, Philips Mr Milind Pappu, President CEO, Nipro Mr Anish Bafna, CEO & MD, Healthium Mr Bhargav Kotadia, Managing Director, SMT Ms Gayathri Nair, Head- Regulatory Affairs, Meril Lifesciences
16:30-18:00	Session 2: Quality Diagnostics for All: Innovations, Enablers, and the Future Roadmap for India
	Diagnostics for All: Innovations, Enablers, and the Future Roadmap for India" will serve as a pivotal platform to catalyze change in India's healthcare landscape. By fostering dialogue and collaboration, this session aims to pave the way for a future where diagnostics are not only cutting-edge but also inclusive, ensuring healthier communities and a sustainable healthcare system for India. The diagnostics sector in India is entering a new era- driven by innovations in Al, genomics, point-of-care testing, biosensors, and connected health solutions. As demand for timely, decentralized, and affordable diagnostics grows, the role of innovators, manufacturers, and ecosystem enablers becomes pivotal. India's opportunity lies not only in creating cutting-edge diagnostic solutions, but also in scaling and manufacturing them affordably, ensuring access across the country and positioning itself as a global supply hub. This requires convergence between startups, established diagnostic manufacturers, government policies, digital platforms, and investment frameworks.



This session will explore the next wave of diagnostic innovation, understand manufacturers' needs and challenges, and lay out a future-forward roadmap that ensures innovation, access, and scale go hand in hand. Key Takeaways • Transformative Technologies: India's diagnostics sector is being reshaped by Al, digital health, and molecular technologies, supported by government investment, startup dynamism, and enabling policies. • Future Roadmap: The focus ahead lies in scaling emerging technologies, addressing regulatory and workforce challenges, and ensuring equitable access across the country. • Collaborative Ecosystem: Strengthening partnerships among government, industry, academia, and healthcare providers is critical to drive innovation, policy support, and sustainable growth. • Access & Integration: Identifying actionable strategies to enhance affordability, expand accessibility, and integrate diagnostics into India's healthcare system in line with universal health coverage goals. Session Chair: Dr Rajiv Bahl, Secretary to Government of India, Department of Health Research & Director General, Indian Council of Medical Research (ICMR) Session Co-Chair: Mr Awadhesh Chaudhary, Senior Economic Advisor, Department of Pharmaceuticals, Gol Session Moderator: Mr Abhinav Thakur, Managing Director, Accurex Biomedical Government Panelist: • Shri Pramod Meshram, Deputy Drugs Controller (India), CDSCO IVD Division • Dr Neelima Mishra, Director, NIB • Mr Pankaj Johri, Director, NABL Industry Speakers: • Mr S Kanwar, Managing Director, J Mitra • Mr Rajeev Gautam, Managing Director, J Mitra • Mr Rajeev Gautam, Senior Corporate Officer- HORIBA, Ltd., Japan; President-HORIBA India • Mr Prabir Saha, Director, Diatek Healthcare P Ltd • Mr Ajay Kumar Bhatt, CEO, Medsource Ozone Biomedicals • Mr Neeraj Gupta, Founder & CEO, Genes 2Me Pvt Ltd • Mr L B Gautam, Senior GM-Government Business, Transasia Bio-Medicals	<u> </u>	
Session Chair: Dr Rajiv Bahl, Secretary to Government of India, Department of Health Research & Director General, Indian Council of Medical Research (ICMR) Session Co-Chair: Mr Awadhesh Chaudhary, Senior Economic Advisor, Department of Pharmaceuticals, Gol Session Moderator: Mr Abhinav Thakur, Managing Director, Accurex Biomedical Government Panelist: Shri Pramod Meshram, Deputy Drugs Controller (India), CDSCO IVD Division Dr Neelima Mishra, Director, NIB Mr Pankaj Johri, Director, NABL Industry Speakers: Mr R S Kanwar, Managing Director, Allengers Ms Veena Kohli, Managing Director, Vanguard Diagnostics Mr Jatin Mahajan, Managing Director, J Mitra Mr Rajeev Gautam, Senior Corporate Officer- HORIBA, Ltd., Japan; President-HORIBA India Mr Prabir Saha, Director, Diatek Healthcare P Ltd Mr Ajay Kumar Bhatt, CEO, Medsource Ozone Biomedicals Mr Neeraj Gupta, Founder & CEO, Genes2Me Pvt Ltd		 manufacturers' needs and challenges, and lay out a future-forward roadmap that ensures innovation, access, and scale go hand in hand. Key Takeaways Transformative Technologies: India's diagnostics sector is being reshaped by AI, digital health, and molecular technologies, supported by government investment, startup dynamism, and enabling policies. Future Roadmap: The focus ahead lies in scaling emerging technologies, addressing regulatory and workforce challenges, and ensuring equitable access across the country. Collaborative Ecosystem: Strengthening partnerships among government, industry, academia, and healthcare providers is critical to drive innovation, policy support, and sustainable growth. Access & Integration: Identifying actionable strategies to enhance affordability, expand accessibility, and integrate diagnostics into India's healthcare system in line
Pharmaceuticals, Gol Session Moderator: Mr Abhinav Thakur, Managing Director, Accurex Biomedical Government Panelist: Shri Pramod Meshram, Deputy Drugs Controller (India), CDSCO IVD Division Dr Neelima Mishra, Director, NIB Mr Pankaj Johri, Director, NABL Industry Speakers: Mr R S Kanwar, Managing Director, Allengers Ms Veena Kohli, Managing Director, Vanguard Diagnostics Mr Jatin Mahajan, Managing Director, J Mitra Mr Rajeev Gautam, Senior Corporate Officer- HORIBA, Ltd., Japan; President-HORIBA India Mr Prabir Saha, Director, Diatek Healthcare P Ltd Mr Ajay Kumar Bhatt, CEO, Medsource Ozone Biomedicals Mr Neeraj Gupta, Founder & CEO, Genes2Me Pvt Ltd		Session Chair: Dr Rajiv Bahl, Secretary to Government of India, Department of Health Research & Director General, Indian Council of Medical Research (ICMR)
Government Panelist: Shri Pramod Meshram, Deputy Drugs Controller (India), CDSCO IVD Division Dr Neelima Mishra, Director, NIB Mr Pankaj Johri, Director, NABL Industry Speakers: Mr R S Kanwar, Managing Director, Allengers Ms Veena Kohli, Managing Director, Vanguard Diagnostics Mr Jatin Mahajan, Managing Director, J Mitra Mr Rajeev Gautam, Senior Corporate Officer- HORIBA, Ltd., Japan; President-HORIBA India Mr Prabir Saha, Director, Diatek Healthcare P Ltd Mr Ajay Kumar Bhatt, CEO, Medsource Ozone Biomedicals Mr Neeraj Gupta, Founder & CEO, Genes2Me Pvt Ltd		· · · · · · · · · · · · · · · · · · ·
 Shri Pramod Meshram, Deputy Drugs Controller (India), CDSCO IVD Division Dr Neelima Mishra, Director, NIB Mr Pankaj Johri, Director, NABL Industry Speakers: Mr R S Kanwar, Managing Director, Allengers Ms Veena Kohli, Managing Director, Vanguard Diagnostics Mr Jatin Mahajan, Managing Director, J Mitra Mr Rajeev Gautam, Senior Corporate Officer- HORIBA, Ltd., Japan; President-HORIBA India Mr Prabir Saha, Director, Diatek Healthcare P Ltd Mr Ajay Kumar Bhatt, CEO, Medsource Ozone Biomedicals Mr Neeraj Gupta, Founder & CEO, Genes2Me Pvt Ltd 		
 Dr Neelima Mishra, Director, NIB Mr Pankaj Johri, Director, NABL Industry Speakers: Mr R S Kanwar, Managing Director, Allengers Ms Veena Kohli, Managing Director, Vanguard Diagnostics Mr Jatin Mahajan, Managing Director, J Mitra Mr Rajeev Gautam, Senior Corporate Officer- HORIBA, Ltd., Japan; President-HORIBA India Mr Prabir Saha, Director, Diatek Healthcare P Ltd Mr Ajay Kumar Bhatt, CEO, Medsource Ozone Biomedicals Mr Neeraj Gupta, Founder & CEO, Genes2Me Pvt Ltd 		
 Mr Pankaj Johri, Director, NABL Industry Speakers: Mr R S Kanwar, Managing Director, Allengers Ms Veena Kohli, Managing Director, Vanguard Diagnostics Mr Jatin Mahajan, Managing Director, J Mitra Mr Rajeev Gautam, Senior Corporate Officer- HORIBA, Ltd., Japan; President-HORIBA India Mr Prabir Saha, Director, Diatek Healthcare P Ltd Mr Ajay Kumar Bhatt, CEO, Medsource Ozone Biomedicals Mr Neeraj Gupta, Founder & CEO, Genes2Me Pvt Ltd 		
 Industry Speakers: Mr R S Kanwar, Managing Director, Allengers Ms Veena Kohli, Managing Director, Vanguard Diagnostics Mr Jatin Mahajan, Managing Director, J Mitra Mr Rajeev Gautam, Senior Corporate Officer- HORIBA, Ltd., Japan; President-HORIBA India Mr Prabir Saha, Director, Diatek Healthcare P Ltd Mr Ajay Kumar Bhatt, CEO, Medsource Ozone Biomedicals Mr Neeraj Gupta, Founder & CEO, Genes2Me Pvt Ltd 		
 Mr R S Kanwar, Managing Director, Allengers Ms Veena Kohli, Managing Director, Vanguard Diagnostics Mr Jatin Mahajan, Managing Director, J Mitra Mr Rajeev Gautam, Senior Corporate Officer- HORIBA, Ltd., Japan; President-HORIBA India Mr Prabir Saha, Director, Diatek Healthcare P Ltd Mr Ajay Kumar Bhatt, CEO, Medsource Ozone Biomedicals Mr Neeraj Gupta, Founder & CEO, Genes2Me Pvt Ltd 		•
		 Mr R S Kanwar, Managing Director, Allengers Ms Veena Kohli, Managing Director, Vanguard Diagnostics Mr Jatin Mahajan, Managing Director, J Mitra Mr Rajeev Gautam, Senior Corporate Officer- HORIBA, Ltd., Japan; President-HORIBA India Mr Prabir Saha, Director, Diatek Healthcare P Ltd Mr Ajay Kumar Bhatt, CEO, Medsource Ozone Biomedicals Mr Neeraj Gupta, Founder & CEO, Genes2Me Pvt Ltd

Day 2: September 5, 2025	
1030 - 1730	Buyer Seller Meet (Prefixed B2B, G2B meetings)
1030 - 1145	Global Regulatory Submission Presentations- Country 1 & 2
	Government Panellist:
	Mr Aseem Sahu, Deputy Drug Controller, CDSCO
	Session Moderator:



	• Dr Rajiv Chhibber, Vice President - External Affairs, Sahajanand Medical
	Technologies (SMT)
	Global Regulators:
	• Cuba
	Russia
1200 1220	Session 3: Strongthoning India/s Madical Daviss Parks: Boodman for Clabal Standard
1200 - 1330	Strengthening India's Medical Device Parks: Roadmap for Global-Standard Manufacturing
	This session explores strategies to elevate India's medical device parks to global
	manufacturing standards, aligning with the National Medical Devices Policy, 2023, and initiatives like Make in India and Aatmanirbhar Bharat. With India's MedTech market projected to reach \$30 billion by 2030, medical device parks are pivotal in reducing import dependency and boosting exports. The discussion will focus on infrastructure development, regulatory harmonization, innovation through R&D, and workforce skilling to position India as a global MedTech hub.
	 Key Takeaways India's medical device parks are pivotal for reducing import dependency (currently 70-80%) and achieving a \$30 billion market by 2030. Strategic investments in infrastructure, R&D, and skill development are critical for global-standard manufacturing.
	Collaborative efforts between government, industry, and academia will drive innovation and competitiveness.
	Session Chair: Shri R P Singh, IAS, Joint Secretary, Department of Pharmaceuticals, Gol
	Session Moderator: Mr Rohit Sahani, Managing Director & Partner, BCG
	Government Panellist:
	Shri Rakesh Kumar Singh, IAS, CEO, YEIDA, Medical Device Park, Uttar Pradesh
	Mr Rajesh Rathod, Executive Director, MPIDC, Madhya Pradesh
	 Ms Selvi A Catherine Saranya, IAS, Executive Director, State Industries Promotion Corporation of Tamil Nadu (SIPCOT)
	 Dr Jitendra Sharma, Managing Director and Founder CEO, Andhra Pradesh MedTech Zone (AMTZ)
	Shri Arvind Kumar, Director General, Software Technology Parks of India (STPI)*
	 Industry Speakers: Mr Himanshu Baid, Managing Director, Polymedicure (UP, MDP) Mr Prashant Krishnan, CEO, TI Medical (UP, MDP) Mr Vijay Gopal, Director, S3V Vascular (Tamil Naidu, MDP) Dr Dhanasekaran, Director, Genuine Biosystems (Tamil Naidu, MDP)
1400 - 1530	Meeting with Procurement Agencies- Chaired by DoP, GoI (By invite only)
	<u>Chair</u> : Shri R P Singh, IAS, Joint Secretary, Department of Pharmaceuticals, Gol
	 <u>Co-Chair:</u> Shri Rakesh Kumar, Deputy Director General, Department for Promotion of Industry and Internal Trade (DPIIT)
	• Session Moderator: Mr Siddhartha Bhattacharyya, Secretary General, NATHEALTH
	State Government Representatives
	Hospitals- Government & Private



1400 - 1500	Lunch
1500 - 1615	Global Regulatory Submission Presentations – Country 3 & 4
	Government Panellist: Mr Aseem Sahu, Deputy Drug Controller, CDSCO Session Moderator: Mr Gaurav Agarwal, MD, Innvolution Global Regulators: United Kingdom Brazil
1615 – 1745	Session 4: SAMD, AI & Cyber Security: Innovations, Enablers, and the Future Roadmap for India
	This session explores the transformative role of Software as a Medical Device (SaMD) and associated technologies (AI, IoT, cloud computing) in advancing India's MedTech sector. Aligned with the National Medical Devices Policy, 2023, and initiatives like Make in India and Aatmanirbhar Bharat, it addresses how SaMD can drive India's \$30 billion MedTech market by 2030, reduce import dependency and establish global leadership in digital health. The discussion will focus on innovation, technology integration, regulatory enablers, and workforce skilling to create a robust SaMD ecosystem. Key Takeaways SaMD, powered by AI, IoT, and cloud technologies, can drive India's MedTech market to \$30 billion by 2030. Robust regulatory frameworks and technology integration are critical for scaling SaMD solutions. Skilling and ecosystem support will enable India to compete globally in digital health innovation.
	 Session Chair: Smt Kavita Bhatia, Scientist G and Group Coordinator, Ministry of Electronics & Information Technology (MeitY), Gol* / Smt Sunita Verma, Scientist G and Group Coordinator, R&D Division, MeitY, Gol* Session Moderator: Mr Lalit Mistry, Partner & Co-Lead, Healthcare, KPMG Government Panelist: Dr Jitendra Kumar, Managing Director, BIRAC* Dr Ravishankar Ramanathan, PhD, CEO, WIN Centre of Excellence for Medtech, IIT Madras Industry Speakers: Dr Rakesh Mullick, Chief Scientist, Wipro GE HealthCare Dr Vibhav Garg, President- Global Government Affairs, Meril Lifesciences Mr Balamurugan Ramasamy, VP, HCL Technologies Limited Mr Krishna Bodnapu, Executive Vice Chairman & Managing Director, Cyient



Day 3: September 6, 20	125
1030 - 1400	Buyer Seller Meet (Prefixed B2B, G2B meetings)
1100 - 1230	Meeting with Global Regulators: Shaping a Future-Ready MedTech Regulatory Ecosystem
	Session Brief: As India charts its path toward becoming a developed nation by 2047 under the vision of Viksit Bharat, a future-ready, innovation-friendly regulatory framework is vital for the growth of the MedTech sector. This Open House aims to serve as a dynamic, solution-focused dialogue between regulators (central, state, and global) and industry stakeholders to co-create a regulatory roadmap that ensures quality, innovation, access, and global competitiveness. With India's growing aspiration to become a MedTech manufacturing and innovation hub, the session will focus on streamlining regulatory pathways, aligning with international standards, and enabling timely approvals for new-age technologies-while keeping patient safety and public trust at the core.
	 Key Discussion points: Innovation Pathways: Creating adaptive regulatory frameworks for new-age technologies like AI/ML-based diagnostics, wearable devices, and personalized implants Decentralized Regulation: Strengthening the role of state regulators in supporting compliance, inspections, and capacity-building Single-Window Clearance: Strategies to reduce time-to-market through integrated digital approval mechanisms Quality & Patient Safety: Ensuring robust post-market surveillance, recall mechanisms, and quality certifications Support for Indigenous Manufacturing: Leveraging regulatory incentives for local manufacturing and product localization
	Session Chair: Shri Nitin Kumar Yadav, Additional Secretary, Department of Commerce, Government of India, GoI*
	Session Co-Chair: Dr Rajeev Singh Raghuvanshi, DCGI, Drug Controller General of India*
	Government Panelist: • Ms S Ahlladini Panda, Member Secretary, NPPA, Gol
	• Ms Gayatri Nair, Economic Advisor, DoP, Gol
	• Mr Aseem Sahu, Deputy Drug Controller, CDSCO, Gol
	 Mr Aditya Das, Head of Medical Equipment and Hospital Planning Department (MHD), Bureau of Indian Standards
	• Mr Hitender Sahu, Director, Department of Pharmaceuticals, Gol
	Session Moderator: Mr Himarchy Baid, Managing Director, Bolymodicure
	 Mr Himanshu Baid, Managing Director, Polymedicure Global Regulators from Countries:
	 Myanmar Kyrgyzstan Ethiopia Mali



		· Laos
1230 – 1330	0	Lunch with Global Regulators (By invite)
1300 – 140	0	Lunch

*Invited